On the sixth anniversary of Mayo v. Prometheus, what impact has the US Supreme Court decision had on patent subject-matter eligibility and the prosecution of biotech-related patent applications before the US Patent and Trademark Office?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mayo Collaborative Services v. Prometheus Laboratories, Inc. 132 S. Ct. 1289 (2012).
Alice Corp. v. CLS Bank International 134 S. Ct. 2347 (2014).
Haanes, E. J. & Cànaves, J. M. Nat. Biotechnol. 30, 758–760 (2012).
Fox, J. L. Nat. Biotechnol. 30, 373–374 (2012).
Malecek, M.J. et al. Petition for Writ of Certiorari, Sequenom, Inc. v. Ariosa Diagnostics Inc., et al., No. 15-1182, https://www.scotusblog.com/wp-content/uploads/2016/04/Sequenom-Cert-Petition.pdf (2016).
Eisenberg, R. S. J. Sci. Technol. Law 21, 256–286 (2015).
Minssen, T. & Nilsson, D. Queen Mary J. Intellect. Prop. 2, 376–388 (2012).
Ariosa Diagnostics, Inc. v. Sequenom, Inc. 788 F.3d 1371 (2015).
Holman, C. M. Geo. Mason Law Rev. 23, 901–940 (2016).
Valoir, T. HIPLA comments on patent subject matter eligibility. https://www.uspto.gov/sites/default/files/documents/RT2%20Comments%20Houston%20IP%20Law%20Association.pdf (2017).
Bahr, R.W. Changes in examination procedure pertaining to subject matter eligibility, recent subject matter eligibility decision (Berkheimer v. HP, Inc.). USPTO https://www.uspto.gov/sites/default/files/documents/memo-berkheimer-20180419.PDF (2018).
Chao, B. & Mapes, A. Patently-O Patent Law J. 10, 10–14, https://cdn.patentlyo.com/media/2016/04/Chao.2016.PersonalizedMedicine.pdf (2016).
Ledford, H. Nature 536, 382 (2016).
Association for Molecular Pathology v. Myriad Genetics, Inc. 133 S. Ct. 2107 (2013).
USPTO. RCE outreach statistics (USPTO, 2012).
Gaudry, K., Grab, L. & McKeon, T.W. IPWatchdog https://www.ipwatchdog.com/2015/07/12/trends-in-subject-matter-eligibility-for-biotechnology-inventions/id=59738/ (2015).
Davis, R. Law360 https://www.law360.com/articles/783604/kappos-calls-for-abolition-of-section-101-of-patent-act (2016).
Sachs, R.R. Twenty-two ways Congress can save section 101. Bilski Blog https://www.bilskiblog.com/2015/02/twenty-two-ways-congress-can-save-section-101/ (2015).
Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited, West-Ward Pharmaceuticals Corp. 887 F.3d 1117 (2018).
Bahr, R.W. Recent subject matter eligibility decision: Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals. USPTO https://www.uspto.gov/sites/default/files/documents/memo-vanda-20180607.PDF (2018).
Vanda Pharmaceuticals Inc. and Aventisub LLC v. Roxane Laboratories, Inc. 203 F. Supp.3d 412 (2016).
USPTO subject matter eligibility examples: life sciences (2016).
Acknowledgements
The research was supported, in part, by a Novo Nordisk Foundation Grant for a scientifically independent Collaborative Research Programme in Biomedical Innovation Law (grant no. NNF17SA027784).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Aboy, M., Crespo, C., Liddell, K. et al. Mayo’s impact on patent applications related to biotechnology, diagnostics and personalized medicine. Nat Biotechnol 37, 513–518 (2019). https://doi.org/10.1038/s41587-019-0111-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0111-5
This article is cited by
-
Mapping the patent landscape of medical machine learning
Nature Biotechnology (2023)
-
Relieving patent-eligibility barriers in biotech with a preparation or treatment method
Nature Biotechnology (2022)
-
Understanding the basics of patenting
Nature Biotechnology (2020)
-
Reply to C.D. Richter
European Journal of Human Genetics (2020)
-
One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?
Nature Biotechnology (2020)